AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

[News]

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

More... (http://www.news-medical.net/news/20120929/AVEO-submits-tivozanib-NDA-with-FDA-for-treatment-of-advanced-renal-cell-carcinoma.aspx)